CORRECTION article

Front. Pharmacol., 19 February 2021

Sec. Inflammation Pharmacology

Volume 11 - 2020 | https://doi.org/10.3389/fphar.2020.635927

Corrigendum: Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease

  • 1. Department of Basic Sciences, School of Dentistry, São Paulo State University (UNESP), Araçatuba, Brazil

  • 2. Multicenter Postgraduate Program in Physiological Sciences, Brazilian Society of Physiology, School of Dentistry, São Paulo State University (UNESP), Araçatuba, Brazil

  • 3. Department of Stomatology, Bauru School of Dentistry, University of São Paulo, Bauru, Brazil

  • 4. Department of Biological Science, Bauru School of Dentistry, University of São Paulo, Bauru, Brazil

In the original article, there was a mistake in Figure 3 as published. On Figure 3 panel F, an error was made when assembling the representative imagens on the board, and the same image was included twice for the SHR Control group and SHR Telm + PD group. The correct representative image for the SHR Control group was included and the corrected Figure 3 appears below.

FIGURE 3

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Summary

Keywords

telmisartan, AT1 blocker, bone metabolism, spontaneous hypertensive rats, periodontal disease, osteoblast, osteoclast, cytokines

Citation

Brito VGB, Patrocinio MS, Linjardi MC, Emanuelli Alves Barreto A, Frasnelli SCT, Lara V, Santos CF and Oliveira SHP (2021) Corrigendum: Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease. Front. Pharmacol. 11:635927. doi: 10.3389/fphar.2020.635927

Received

30 November 2020

Accepted

23 December 2020

Published

19 February 2021

Volume

11 - 2020

Edited and reviewed by

Ulrike Garscha, University of Greifswald, Germany

Updates

Copyright

*Correspondence: Sandra Helena Penha Oliveira,

This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics